General
Programmed topics
- Finding the therapeutic window; dose finding challenges
- Clinicians’ perspective on optimized dosing schedules
- Personalised dosing: reduction and stopping
- What can we learn from anti-cancer biologics?
- Sharing trade secrets; combine knowledge between biologics and diseases
- Deeper understanding of the PK of biologics
- Clinical pharmacology to enable the development of personalised/stratified medicines
- Impact of antibody structure and pharmacogenetics on PK
- Models for immunogenicity of biologics: how to prevent, how to handle?
- The regulator’s view: ‘How much use is in the label’?
- The pharmaceutical industry’s view on TDM
- Point of care and dashboard applications in practice
- Patient perspective on TDM
There will be a networking reception after the symposium.
Date and Location
Costs and registration
Industry delegates € 200,–
Physicians/Academics € 100,– * use code HBTDMsymposium50 to get a discount.
Phd students/Fellows € 50,– *use code HBTDMsymposium75 to get a discount.
Prices are VAT inclusive.
Accreditation has been requested for: NVN, CGR, NVDV, MDL, NVR & ZA (pending)
Contact
If you have any questions, please contact TDMbiologics2022@sanquin.nl
Organising committee
– Dr. Floris Loeff, Sanquin, Amsterdam, the Netherlands
– Dr. Mark Löwenberg, Amsterdam University Medical Centers, the Netherlands
– Dr. Gertjan Wolbink, Reade and Sanquin, Amsterdam, the Netherlands
Steering committee
– Prof. Geert D’Haens, Amsterdam University Medical Centers, the Netherlands
– Dr. Zoé van Kempen, Amsterdam University Medical Centers, the Netherlands
– Prof. Ron Mathôt, Amsterdam University Medical Centers, the Netherlands
– Dr. Theo Rispens, Sanquin, Amsterdam, the Netherlands
– Prof. Phyllis Spuls, Amsterdam University Medical Centers, the Netherlands
– Dr. Annick de Vries, Sanquin, Amsterdam, the Netherlands